Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d three years and older are planned to enroll in the trial, which is targeted to be conducted in 10 to 15 sites across the US, Europe and Canada. The study will comprise ABH001 applications sufficient to cover the surface area of the wound, applied topically every 4 weeks with protocol-specified dressings until healed or for up to 24 weeks.

"We are excited that Shire Regenerative Medicine has launched this trial," said Brett Kopelan , Executive Director of the Dystrophic EB Research Association of America (DebRA ) and father to a 5-year-old girl with recessive dystrophic EB.  "While there is currently no cure for EB, I am encouraged that ABH001 is…targeting the chronic wounds that are the hallmark of this disease. I applaud Shire for pushing this forward and look forward to working closely with them as the trial progresses."  

"We are very eager to begin evaluating ABH001 as a potential wound treatment option for people with EB. We believe it has the potential to initiate and continue wound healing in this patient population," said Jeff Jonas , MD, President of Shire Regenerative Medicine. "We are committed to developing regenerative medicine solutions that enable people with life-altering conditions to lead better lives, and are encouraged by the fast track and orphan drug designations we have received to further develop this potential therapy for people, most often young children, suffering from this devastating condition."

Shire is also developing an intravenous protein replacement therapy for the treatment of dystrophic EB, which the company's Human Genetic Therapies business recently acquired from Lotus Tissue Repair, Inc. Initiation of this pivotal trial of ABH001 for patients with EB further demonstrates Shire's commitment to developing a portfolio of products targeted toward patients who suffer from this di
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 The College ... first private college in the Mid-Hudson Region to be ... now begin accepting applications from qualified “high-technology” businesses that ... are very pleased to have been selected for the ... Cuomo’s transformative initiative to stimulate economic development in New ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary ... by the Jeffrey Epstein VI Foundation , have shown ... identified for elimination. These aggressive cells are the driver mutations ... topological map of what to look for when examining tumors, ... tumor cells can be extracted from biopsy, it,s very difficult ...
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... Chester, NJ (PRWEB) August 21, 2014 ... of personal selling optimization technology and services for ... publication of “Grading Pharma’s Use of New Commercial ... of Measurement & Analytics. , The article examines ... marketing yield that are being tested in the ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... cells are not pampered pushovers. O,Reilly et al. report ... molding their environment to control their division and differentiation., ... cradle them in a structure called the niche. The ... their behavior, determining whether they reproduce and specialize. The ...
... from Chinese Health Authorities to Launch Final ... Clinical Trial for ... Inc.,today announced the appointment of Dr. Geert Cauwenbergh as Chief ... Cauwenbergh has been assisting RHEI Pharmaceuticals since August 1, 2008,in ...
... 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ), ... and marketing biopharmaceutical products,primarily in China, announces that ... Morgan Stanley Global Healthcare Unplugged Conference in New,York ... A copy of the latest investor presentation ...
Cached Biology Technology:RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 2RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 3RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer 4
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... of Health has awarded the Oklahoma Medical Research Foundation ... on anthrax and the bacteria,s effects on humans. ... and his colleagues have studied the human immune response ... for Human Immunology. The original funding came soon after ... heels of the terrorist attacks of Sept. 11, 2001. ...
(Date:8/20/2014)... athletes who have suffered concussions ready to return to ... that high school athletes who head back on the ... significant regression in their abilities to simultaneously walk and ... in changes in their balance and/or altered walking speed, ... the 12 had returned to activity in less than ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Previously unknown molecules and regulatory pathways in human ... effort of the Medizinische Poliklinik, Munich, the University ... Research Center, sanofi-aventis, and Genomatix Software GmbH. , ... the National Academy of Sciences of the United ...
... of the biggest problems in fighting breast cancer is ... , Researchers at the University of Michigan hope to ... for the presence of metabolites associated with breast cancer. ... award, which funds promising, high-risk, high reward research proposals ...
... from two universities in Italy and Virginia Tech in ... protein that is responsible for the production xanthurenic acid ... plays a key role in the sexual reproduction of ... Interfering with the formation of XA could be an ...
Cached Biology News:Researchers win money to develop breath test to detect breast cancer 2Oxidation defense in mosquitoes benefits malaria parasite 2
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... and BR4i refrigerated multifunction centrifuges are equally capable ... a low sound level with a large range ... AUTO-LOCK rotor exchange system without tools ensures that ... seconds. Instant rotor exchange (5 sec.) ...
... Jouan B4i ventilated and BR4i refrigerated multifunction centrifuges ... speed operation at a low sound level with ... for biocontainment. Their AUTO-LOCK rotor exchange system without ... for use within seconds. Instant rotor ...
Biology Products: